Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000573710 | SCV000672267 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-02 | criteria provided, single submitter | clinical testing | The c.2505+4G>A intronic variant results from a G to A substitution 4 nucleotides after coding exon 16 in the SMARCA4 gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Loss-of-function variants in SMARCA4 are known to cause rhabdoid tumor predisposition syndrome including small cell carcinoma of the ovary-hypercalcemic type (SCCOHT); however, such associations with neurodevelopmental disorders are exceedingly rare (Kosho T et al. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):262-75; Jelinic P et al. Nat Genet. 2014 May;46(5):424-6). Based on the supporting evidence, the association of this alteration with rhabdoid tumor predisposition syndrome is unknown; however, the association of this alteration with Coffin-Siris syndrome is unlikely. |
| Labcorp Genetics |
RCV000646877 | SCV000768662 | likely benign | Rhabdoid tumor predisposition syndrome 2 | 2024-12-04 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV001809654 | SCV002056837 | uncertain significance | Intellectual disability, autosomal dominant 16 | 2021-07-15 | criteria provided, single submitter | clinical testing |